Piper Sandler Reiterates Overweight Rating on DexCom (DXCM)

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $90.00 price target on DexCom (NASDAQ: DXCM).

The analyst commented, "We are hosting another installment of our Bull vs. Bear debate series within the Medtech group at Piper Sandler with DXCM the focus of today's debate. DXCM shares remain contested given several headwinds including competitive dynamics in the domestic basal DME market. Topics discussed on today's call include end market growth, sales force alignment, competitive encroachment and valuation, among others. Ultimately, our OW rating is reiterated."

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $69.70 yesterday.

You May Also Be Interested In